Related Experiment Videos
A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C
1Division of Gastroenterology and Hepatology, Kawasaki Chuo Hospital, Japan.
Hepatology (Baltimore, Md.)
|September 1, 1994
Summary
Ursodeoxycholic acid (UDCA) effectively improved liver function in chronic hepatitis C patients at higher doses. Higher UDCA doses (600 and 900 mg/day) significantly reduced liver enzymes and altered bile acid hydrophobicity.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Chronic hepatitis C (HCV) is a significant liver disease.
- Bile acid metabolism plays a role in liver health.
- Ursodeoxycholic acid (UDCA) is a bile acid with potential therapeutic effects.
Purpose of the Study:
- To investigate the effect of different doses of UDCA on liver function tests.
- To examine the impact of UDCA on bile acid metabolism in chronic hepatitis C patients.
- To correlate changes in bile acid hydrophobicity with liver enzyme levels.
Main Methods:
- Multi-center randomized controlled dose study.
- 17 control patients and 92 patients receiving UDCA (150, 600, or 900 mg/day) for 16 weeks.
- Serum liver parameters (ALT, GGT) and bile acid composition (HPLC) were analyzed.
Main Results:
- Significant decrease in ALT and GGT observed with 600 and 900 mg/day UDCA.
- UDCA fraction increased dose-dependently and was significantly higher than controls (p < 0.001).
- Decreased hydrophobicity index correlated with reduced ALT and GGT in higher dose groups.
Conclusions:
- Higher doses of UDCA (600 and 900 mg/day) demonstrate efficacy in improving liver function tests in chronic hepatitis C.
- UDCA treatment alters bile acid composition and reduces hydrophobicity, correlating with improved liver enzymes.
- The therapeutic effect of UDCA may be linked to modulation of bile acid hydrophobicity.